Results 111 to 120 of about 719,508 (214)

ERBB RECEPTORS DIMERIZATION DEFINES BREAST CANCERS SUBTYPES AND CLINICAL OUTCOMES: IMPLICATION FOR CANCER THERAPIES

open access: yes, 2016
Breast cancers are classified into categories according to specific criteria, such as histopathological type, tumour grade and more recently the gene expression signature.
Adriana Albini   +6 more
core   +1 more source

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma. [PDF]

open access: yesFront Oncol, 2023
Breitenecker K   +10 more
europepmc   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2955-2973, November 2026.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce   +11 more
wiley   +1 more source

Epidermal Growth Factor Receptor and c-erbB-2 Contents in Unresectable (UICC R1 or R2) Gastric Cancer

open access: yesThe International Journal of Biological Markers, 2003
Background Epidermal growth factor receptor (EGFR) and c-erbB-2 are membrane receptors expressed in a variety of solid human cancers and directly correlated with poor prognosis.
I. García   +5 more
doaj   +1 more source

Correlation of c-erbB-2, EGF and EGFR expression with postoperative survival of patients with advanced carcinoma of the stomach.

open access: yesFolia Histochemica et Cytobiologica, 2010
The c-erbB-2 (HER-2/neu), EGF and EGFR (erbB-1) proteins, members of the epidermal growth factor receptor family, play a role in cell growth by binding to cell membrane receptors.
Katarzyna Guzinska-Ustymowicz   +2 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, Volume 20, Issue 11, Page 2741-2763, November 2026.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Fasting and Refeeding Mediated Phospholipid Remodeling Plays an Important Role in Improving Meat Quality of Aged Laying Hens

open access: yesAnimal Research and One Health, Volume 4, Issue 4, Page 379-390, November 2026.
ABSTRACT This study explored fasting‐induced physiological remodeling effects on meat quality in aged laying hens. Fasting for 15 days (F15) significantly reduced abdominal fat, intermuscular fat width, subcutaneous fat thickness, and liver index versus pre‐fasting (F0) (p < 0.05), which recovered post‐refeeding.
Xiaoran Zhang   +8 more
wiley   +1 more source

Ovarian Carcinoma: Signal Pathways and Clinical Studies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This review synthesizes current knowledge on the pathophysiological mechanisms driven by the Notch, HER2, DNA damage repair (DDR), PI3K/AKT/mTOR, and angiogenesis (VEGF) pathways in ovarian cancer. A key focus is placed on summarizing subsequent targeted therapeutic strategies, detailing the landscape of associated clinical trials and their ...
Yanru Long   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy